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ABSTRACT
Differentiating Celiac Disease, Lactose Intolerance, and
Irritable Bowel Syndrome in the
Primary Care Setting
Sophia M. Larimer
College of Nursing
BYU Master of Science

The purpose of this paper is to assist nurse practitioners (NPs) and other primary care
providers in differentiating between celiac disease (CD), lactose intolerance (LI), and
irritable bowel syndrome (IBS) in adults. The Health Source: Nursing/Academic Edition,
CINAHL, MEDLINE (EBSCO) search engines were utilized to access systematic reviews and
primary research articles published between 2009–2016. Current literature supports that
a thorough history and physical must be conducted and alarming symptoms must be
investigated to rule out worrisome diagnoses. Based on subtle characteristics gathered
from the history and physical, the NP’s examination and testing will help distinguish CD, LI,
and IBS. Nurse practitioners should use a sequential process of examination and testing
(see Figure-1) to distinguish gastrointestinal disorders that share common symptoms.
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Differentiating Celiac Disease, Lactose Intolerance,
and Irritable Bowel Syndrome in the Primary Care Setting
Gastrointestinal (GI) disorders are frequently seen in primary care settings and
commonly include celiac disease (CD), lactose intolerance (LI), and irritable bowel
syndrome (IBS). However, these disorders are often difficult to differentiate because each
condition share common symptoms such as abdominal pain, bloating, gas, and diarrhea.
These often vague and commonplace symptoms make the diagnosis difficult and contribute
to delay in diagnosis. Patients who develop CD as adults gradually experience abnormal
symptoms of diarrhea and steatorrhea, and as a result these patients may perceive their
symptoms as being normal (Brody & Murray, 2014). For example, it takes approximately
one year (and sometimes even as long as 10 years) for patients with CD to be diagnosed
after GI symptoms appear (Ford et al., 2009; Fuchs et al., 2014). Likewise, 10–15% of the
population in the United States is affected by IBS, but only 5–7% are actually diagnosed
(National Digestive Diseases Information Clearinghouse, 2013), and usually only after their
primary care provider (PCP) has referred them to a gastroenterologist (El-Salhy, LomholtBeck, & Gundersen, 2011).
Abdominal complaints comprise 30–50% of reported cases in the primary care setting;
therefore, nurse practitioners (NPs) must be well versed in GI-related disorders. Although
CD, LI, and IBS present with similar symptoms, the pathology differs, and, if misdiagnosed,
irreversible GI damage and nutritional deficiencies might result. According to Pironti et al.
(2010), patients complaining of chronic diarrhea and/or abdominal pain suffer from
microscopic damage due to an underlying pathological process 81% of the time. Therefore,
it is imperative that NPs make accurate and timely diagnoses not only to prevent
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pathological disease processes from ensuing, but to improve their patient’s quality of life
(Schuppan & Zimmer, 2013; Strauch & Cotter, 2011; Thom, Longo, Running, &
Ashley2009). Accordingly, the purpose of this paper is to introduce NPs to a systematic
approach for successfully differentiating CD, LI, and IBS in adults.
Methods
Collectively, there are few systematic reviews and meta-analyses published on
distinguishing CD, IBS, and LI; there are, however, a variety of research studies available on
these topics individually. Data were accessed through several search engines. First, the
Cochrane Database was accessed to identify any meta-analyses studying these disorders
conjointly. Next, the Health Source: Nursing/Academic Edition, CINAHL, MEDLINE (EBSCO)
search engines were used to access articles published in English between 2009–2015.
Search terms included “celiac,” “CD,” “lactose intolerance,” “LI,” “irritable bowel,” “IBS,” and
“diagnose.”
Background Information on CD, LI, and IBS
Celiac Disease
Affecting 0.5–1% of people worldwide, CD is a genetically or autoimmune based chronic
enteropathy of the small intestine that is caused by an intolerance to gluten (Mehdi,
Sakineh, Mohammad, Mansour, & Alireza, 2012; Schuppan & Zimmer, 2013). Gluten is a
complex of water-soluble protein that is a component in wheat, barley, bulgur, durum, rye,
and spelt. Other foods containing gluten that patients might be unfamiliar with, include
beer, candy, gravies, imitation meats or seafood, processed luncheon meats, salad
dressings, soy sauce, self-basting poultry, and some soups (The Mayo Foundation, 2013).
People who have the genetic predisposition for CD typically carry the HLA-DQ2 or HLA-
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DQ8 genes (90% and 10%, respectively) (Schuppan & Zimmer, 2013; Strauch & Cotter,
2011). Patients with genetic-based and autoimmune diseases (especially Turner syndrome,
Down syndrome, type I diabetes mellitus [DM 1], and thyroid disease), as well as firstdegree relatives of patients with CD, are considered to be high risk for developing CD. This
genetic link causes class II human leukocyte antigens to produce autoantibodies against the
enzyme tissue transglutaminase (tTG), which becomes activated in the presence of gluten
(Schuppan & Zimmer, 2013; Strauch & Cotter, 2011). As this autoimmune process
proceeds, it damages the villi lining the mucosa of the small intestine and alters the
environment where nutrients are absorbed (Leffler & Schuppan, 2010). Once diagnosed,
this inflammation can be managed simply by excluding gluten from the diet (El-Salhy et al.,
2011; Ford et al., 2009).
Celiac disease involves a variety of symptoms with both gastrointestinal and systemic
manifestations, usually lasting longer than 3 months. A patient typically presents with
diarrhea, unexplained weight loss, abdominal distention, bloating, dyspepsia, and
flatulence (Schuppan & Zimmer, 2013). It is not uncommon for pain to be specifically
located in the right lower abdomen, and even accompanied by a palpable mass, raising
suspicions of appendicitis or Crohn’s disease (Gikas & Triantafillidis, 2014). Systemic
manifestations of CD include migraines, chronic fatigue, depression, irritability, Duhring’s
dermatitis herpetiformis, oral aphthous ulcers, loss of dental enamel, iron-deficiency
anemia, anorexia, osteoporosis, joint pain, growth failure, short stature, delayed puberty,
amenorrhea, early menopause, reduced fertility, and epilepsy (Boettcher & Crowe, 2013;
Kurppa et al., 2009; Rubio-Tapia, Hill, Ciarán, Calderwood, & Murray, 2013; Strauch &
Cotter, 2011). Patients who presented with coexisting musculoskeletal or neurological
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disorders, diarrhea, abdominal pain, iron-deficiency anemia, or female, were found to have
experience a diagnostic delay before being diagnosed with CD (Fuchs et al., 2014). It is
important for NPs to recognize these systemic manifestations to distinguish CD from other
bowel disorders.
Lactose Intolerance
Lactose intolerance is the most common metabolic food sensitivity, affecting 60–70% of
people worldwide. Approximately 20% of those affected are Europeans and Americans
(Carter & Attel, 2013; Perets et al., 2014). Primary lactose deficiency is the most common
cause of LI and is found most frequently in South America, Africa, Asia, and descendants
from those areas. Secondary lactose deficiency results from injury and inflammation of the
brush border of the small intestine, and can also be caused by bacterial overgrowth,
gastroenteritis, CD, and disorders that cause rapid gastrointestinal motility (Carter & Attel,
2013; Yang et al., 2013). Lactose intolerance usually begins in childhood, but it is most
prevalent in adulthood, because the lactase enzyme progressively decreases over the
lifespan (Boettcher & Crowe, 2013; Furnari et al., 2013; Perets et al., 2014). Lactase
persistence is a term used to describe the capability of being able to digest lactose as an
adult. About two thirds of people in the world do not carry the genetic makeup that allows
for lactase production, and are therefore lactase non-persistent. Genetic testing is available
to identify people who are lactase non-persistent, and can be screened for the C/C (-13910)
genotype (sensitivity 93% and specificity 100%). Additional testing is available for the T/C
(-13910) gene, but these patients can either be lactase persistent or non-persistent
(Baffour-Awuah et al., 2015).
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Lactose is a disaccharide sugar found in dairy products such as milk, yogurt, and cheese
that requires the lactase enzyme to break it down into glucose and galactose. Inadequate
levels of the lactase enzyme result in abdominal discomfort, bloating, gas, and diarrhea,
because undigested lactose in the colon is fermented by bacteria (Boettcher & Crowe, 2013;
Campbell et al., 2010; Carter & Attel, 2013). People with LI can generally tolerate 12 grams
of lactose (1 cup of milk) with symptoms typically beginning when 40 grams of lactose are
ingested. However, if minute amounts of lactose cause distressing symptoms, a rare
disorder called congenital lactase deficiency should be considered (Bolin 2009; Campbell et
al., 2010; Yang et al., 2013). Studies have shown that diarrhea pre-dominant IBS (IBS-D)
patients release greater amounts of inflammatory cells after lactose ingestion compared to
the average person, and find symptom relief with a lactose-free diet (Yang et al., 2014).
Although lactose intolerance is quite common, it can be difficult to differentiate when it
coexists with other disorders, such as IBS and CD.
Irritable Bowel Syndrome
Irritable bowel syndrome affects 10–15% of the world’s population (but most cases are
concentrated in North America), is a set of GI symptoms resulting from irregular relaxation
and contraction of the bowel (National Digestive Diseases Information Clearinghouse,
2013). These symptoms are thought to originate from an alteration in the neuromuscular
function of the smooth muscle lining of the large bowel, which normally relaxes and
contracts in a coordinated rhythm (Bolin, 2009; Ford et al., 2009; Mayo Foundation for
Medical Education and Research, 2011). Evidence has supported the idea that there may be
a connection between excessive microflora in the gut, as well as excessive inflammation
and cytokine activity (Simsek, 2011; Yang et al., 2014). Risk factors for IBS include female
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gender, being between the ages of 20–40, and having psychosocial issues such as anxiety,
depression, personality disorders, and abuse (Chapman, Chen, & Leaver, 2015; Simsek,
2011). The four subtypes of IBS are IBS with diarrhea (IBS-D), IBS with constipation (IBSC), mixed IBS (IBS-M), and unsubtyped IBS (IBS-U). It is notable that IBS-D is the subtype
most frequently confused with other bowel disorders. These patients typically experience
diarrhea and abdominal cramping that mainly occurs in the mornings and after meals.
Other complaints include mucus in the stool, fecal incontinence, feelings of incomplete
evacuation, and pain relieved by defecation (Yang et al., 2013; Yang et al., 2014). Anorexia,
steatorrhea, nocturnal pain or diarrhea, progressive pain, and bloody stools are abnormal
and considered inconsistent with the diagnosis of IBS-D, thus requiring further testing
(Chapman et al., 2015). Irritable bowel syndrome does not cause permanent damage to the
colon or increase the risk for colorectal cancer, although it does severely impact patients’
quality of life. There is a possibility that CD and IBS-D can coexist simultaneously, but there
are conflicting results supporting routine screening of these concurrently (Bakhshipour et
al., 2012; Cash, 2011; El-Salhy et al., 2011; Shahbazkhani et al., 2003).
Current Recommendations for Diagnosing CD
Serological Testing
Diagnosis of CD first begins with serological screening for antibodies (Kurppa et al.,
2009; Tortora et al., 2014). The first-line serological test is the tissue transglutaminase
antibody (IgA a-tTG), which has high sensitivity (90–98%) and specificity (95–97%), is
inexpensive, reliable, and easy to interpret. A “Total IgA” level should be tested
simultaneously because 2% of people with CD have an IgA deficiency and, therefore, might
falsely test negative for IgA a-tTG. Patients who have an IgA deficiency with the initial
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testing for the “IgA a-tTG” and “Total IgA levels” should instead be tested for the IgG antiDGP serum antibody (Brody & Murray, 2014; Ford et al., 2009; Leffler & Schuppan, 2010;
Schuppan & Zimmer, 2013; Thom et al., 2009). It is imperative that patients are not on a
gluten-free diet at the time of lab work because the absence of gluten in the diet gives
falsely normal test results. Patients who have negative serology as a result of being on a
gluten-free diet can be screened via the IgA a-tTG and IgG anti-DGP, and, if either serology
is positive, can proceed to upper endoscopy with small bowel biopsy. If these patients were
on a gluten-free diet and their serology tests are negative, they can be screened for HLADQ2/DQ8 genes. If these genetic markers are negative, it can be assumed that they do not
have CD. On the other hand, if they are positive, these patients should participate in a
gluten challenge diet. Gluten should be present in the diet for at least 2 weeks (optimally 8
weeks), after which serological testing can be performed. If serology is negative, then the
patient should continue a gluten diet for 6 more weeks and be retested for the IgA atTG,Total IgA, and IgG anti-DGP serum antibodies (Brookes & Murray, 2014; Schuppan &
Zimmer, 2013).
Endoscopy
If serology is positive, or if there is a high probability of CD, patients should be referred
to a gastroenterologist for an upper endoscopy and small bowel biopsy (Kurppa et al.,
2009; Rubio-Tapia et al., 2013). As mentioned earlier, CD risk factors include having a firstdegree relative with CD; an autoimmune predisposition, especially type 1 diabetes mellitus
and thyroid disease; or Down syndrome. A person with severe diarrhea, weight loss, and
anemia is at moderate to high risk for having CD (Leffler & Schuppan, 2010). During
endoscopy, at least four biopsies from the duodenum, and at least two biopsies from the
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duodenal bulb must be obtained for accurate results. These samples are graded according
to the MARSH III criteria, which categorizes the severity of the patchy, inflamed lesions of
the small bowel. Debate exists regarding other non-invasive approaches to confirm CD, but
endoscopy with duodenal biopsy is considered the “gold standard” for diagnosis (Kurppa et
al., 2009; Schuppan & Zimmer, 2013; Strauch & Cotter, 2011).
Alternative Testing for CD
Current trends include the use of alternative, less-invasive methods to rule out CD,
especially for the elderly and high-risk populations who might not tolerate endoscopy.
Capsule endoscopy, where an encapsulated camera is ingested and passed through the GI
tract, may be performed if the patient refuses endoscopy and no alarm symptoms are
present. Another option, although not the preferred method, is to use a combination of
antibody titers to predict the amount of damage caused to the small intestine. Tortora and
his team (2014) found that the presence of a-tTG levels (> 62.4) accompanied by elevated
EMA levels (> 45 U/mL) were diagnostic for small bowel damage. Rapid CD tests are
available over-the-counter, but there is little evidence that they are diagnostic for CD.
Korkut et al. (2010) reported that the rapid BioCard Celiac Test was accurate in identifying
all patients who had biopsy-proven CD. However, more research must be conducted to
determine if these rapid tests will be feasible for use in primary care clinics. Ultimately,
endoscopy is the most effective way to diagnose CD, but capsule endoscopy, antibody titers,
and rapid CD tests are alternative options in a non-compliant patient (Bolin, 2009;
Schuppan & Zimmer, 2013; Strauch & Cotter, 2011).
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Current Recommendations for Diagnosing LI
The diagnosis of LI typically involves eliminating dietary lactose for 2 weeks to
determine if symptoms improve. It is sufficient to diagnose a patient with LI if GI
complaints resolve with a lactose free-diet. However, patients who refuse to adhere to a
trial of lactose elimination should proceed with the Lactose Hydrogen Breath Test (HBT)
(sensitivity [69–100%] and specificity [89–100%]), which is non-invasive and costeffective. During the HBT, individuals are given 2g/kg of lactose and are tested for
hydrogen detected in their breath at baseline (fasting for at least 12 hours) and in 30minute intervals for 3 hours. Participants who have a persistent rise in their hydrogen
breath level by 20 ppm are considered HBT positive (Ghoshal, Kumar, Chourasia, & Misra,
2009; Perets et al., 2014; Yang et al., 2013). Efficacy of testing for LI using the HBT was
found to be dependent on whether there was adequate preparation. False positive results
are seen with inadequate pretest fasting or recent smoking (within 6 hours of testing), and
false negative results occur with antibiotic use, diabetes, bacterial overgrowth of the small
intestine, gastric emptying issues, or underlying pulmonary disorders because these factors
can affect the amount of hydrogen levels detected in the breath of patients (Carter & Attel,
2013). An alternative option to the HBT is the Lactose Tolerance Test (LTT), but the LTT
has a lower sensitivity (77–96%) and specificity (76–94%). The HBT is also more
convenient because it monitors the presence of hydrogen, which is a byproduct of
undigested lactose, whereas the LTT requires consecutive blood samples to monitor for
glucose absorption in the blood to indicate whether or not lactose is being broken down in
the small bowel (Furnari et al., 2013).
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A patient who has a negative HBT or LTT but continues to display abnormal GI
symptoms after consuming lactose may receive genetic testing or undergo a biopsy-based
Lactose Intolerance Quick Test (LIQT), which has a sensitivity, specificity, and positive
predictive value nearing 100%. A biopsy sample, taken during endoscopy, from the
duodenum is incubated with lactose for 20 minutes and observed for a reaction. However,
because of its high cost and invasiveness, the PCP should order LIQT testing very
conservatively. Genetic testing of the C/C (-13910) and T/C (-13910) genes is an
alternative option, but is also costly (Carter & Attel, 2013; Furnari et al., 2013; Perets et al.,
2013).
Current Recommendations for Diagnosing IBS-D
Unfortunately, there are no specific tests that directly detect IBS-D; the diagnosis is made
only after ruling out other diseases that have similar GI symptoms (El-Salhy et al., 2011).
Alarm symptoms such as rectal bleeding, anemia, and weight loss are consistent with a
pathological illness, and should be investigated aggressively. This investigation should
include invasive testing such as endoscopy and colonoscopy and a consultation with
gastroenterology. For cases of chronic diarrhea (lasting longer than 2 to 4 weeks) the most
basic serological tests should include a complete blood count, C-reactive protein, and CD
serology (Chapman et al., 2015). Additional tests include stool studies, especially if the
patient has recently traveled abroad or been hospitalized. Essentially, the patient’s specific
clinical history and background should dictate the provider’s choice of testing (Bolin, 2009;
Ford, 2009; National Digestive Diseases Information Clearinghouse, 2013).
If there are no alarm symptoms that need to be investigated, the ROME III criteria
questionnaires provide a positive approach to diagnose IBS. After the exclusion of other
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diagnoses, the ROME III criteria can be used to substantiate a diagnosis of IBS. Examples of
the ROME III criteria include the presence of recurrent abdominal pain or discomfort for at
least 3 days/month in the last 3 months that is associated with two or more of the
following: Improvement with defecation, onset associated with a change in frequency of
stool, or a change in form or appearance of stool (Chapman et al., 2015; Gikas &
Triantafillidis, 2014; Rome Foundation, 2006). A positive Rome III screening correlates
with a three-fold greater likelihood of having IBS (Ford et al., 2013).
On the other hand, there is controversy regarding the use of subjective questionnaires to
substantiate a final diagnosis of IBS-D. Research has shown that questionnaires, including
the ROME III criteria, have a sensitivity and specificity of approximately 70%. This is
attributed to the fact that such questionnaires are solely based on patient-reported
symptoms (Bolin, 2009; Chapman et al., 2015). In fact, 20–50% of patients with confirmed
CD meet the ROME criteria for IBS, highlighting the potential inaccuracy of questionnaires
(Korkut et al., 2010; Rubio-Tapia et al., 2013). In order to address gaps in the ROME III
criteria, Pimentel et al. (2010) developed a questionnaire that focuses on irregular bowel
patterns, such as monitoring intensity of symptoms and their changes over time. It includes
questions regarding unpredictable bowel habits that occurred on a daily basis, and were
correlated most specifically with three or more weekly variable stool forms (Pimentel et al.,
2010). Because IBS-D is technically a diagnosis of exclusion, the key factor is first to exclude
life-threatening illnesses and to keep CD and LI in the differential when assessing a patient
for IBS-D.
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Discussion
Numerous gastrointestinal issues exist, and even as signs and symptoms manifest
themselves, identifying the specific issue can be complicated. Complaints of abdominal
pain, bloating, gas, and diarrhea are often present in CD, LI, and IBS and contribute to a
delay in diagnosis. For example, ordering a series of stool studies is appropriate if the
patient has recently traveled internationally or has been hospitalized. Likewise, when CD is
the top differential, it is crucial that the NP screens for a family history of CD and other
autoimmune diseases. The NP must also thoroughly evaluate the patient for systemic
manifestations of CD such as anemia, dermatitis herpetiformis, dental enamel defects,
aphthous ulcers, infertility, and osteoporosis. When IBS-D is highly suspected, at the very
least a CBC, CRP, and CD serology should be analyzed. On the other hand, it is possible for
different combinations of CD, LI, and IBS to coexist.
Limitations
There are several limitations of this literature review, many of which are attributable to
the fact that some information was gathered from studies performed worldwide. Celiac
disease, LI, and IBS each have an effect on specific international populations, and
synthesizing data into one composition of evidence could influence the results that were
obtained. Many of the studies that were pertinent to LI involved persons of Asian descent.
The majority of these studies were performed on adults ages 18–75, and results might not
be as valuable in assisting NPs in addressing GI issues in the pediatric population. There
was no personal benefit, bias, or monetary gain in the process of collecting published
literature.
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Conclusion
Celiac disease, LI, and IBS present with similar common symptoms, which can be
misleading and contribute to a delay in diagnosis. The NP must be exceptionally thorough
in obtaining the patient’s history and performing the physical examination in order to
identify subtle clues that would direct him or her toward the correct diagnosis. A patient’s
age, ethnicity, gender, family history, psychosocial history, recent travel and
hospitalization, diet, and timing of symptoms should be addressed. It is critical that
patients with alarm symptoms (fatigue, weight loss, nocturnal diarrhea, and blood in the
stool) are referred to gastroenterology for more aggressive testing, which would likely
involve endoscopy. The NP can use the algorithm (Figure-1) and table (Table-1) provided
when he or she encounters patients presenting with symptoms such as abdominal pain,
bloating, gas, and diarrhea. These should be referenced and utilized in accordance with the
patient’s clinical history and physical examination. However, the NP should also consider
other differentials and order additional testing that would be appropriate for the
individual’s presentation. The purpose of this paper is to prepare NPs to identify patients
who are affected by CD, LI, or IBS in order to quickly and efficiently provide treatment
options and improve their patients’ quality of life. Therefore, it is critical for NPs to be
prepared with a process to distinguish bowel disorders, prioritize differential diagnosis,
and order appropriate tests that would guide them in their diagnosis of CD, LI, and IBS, and
furthermore prepare them with tests that consulting specialists might anticipate.
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Table-1. Characteristics differentiating CD, LI, and IBS
Disease
Type

Population

1% of world
Males and
females

Celiac
Disease

All ages

Risk Factors

Genetics:
HLA-DQ2 &
DQ8 genes
1° or 2° relative
with CD

All ethnicities, but Having another
most prevalent in autoimmune disease
Europeans

Irritable
Bowel
Syndrome

10–15%
worldwide
Females
Ages 20–40

Signs & Symptoms

Typical symptoms:
Anorexia
Diarrhea
Bloating Abdominal pain
Systemic symptoms*

Mental health history Pain relieved by defecation
(anxiety, depression, Varying stool forms (>3/wk)
personality disorders,
Mucus in the stool
history of abuse)
Bloating
Family history

North America

Abdominal Pain
Cramping

Timing
of Symptoms
Daily

IgA-tTG &
Total IgA.

Symptoms
present
gradually

If Total IgA is
deficient, then test
the
IgG anti-DGP

Symptoms
have been
present longer If serology is
than 3 mos.
positive, proceed
with endoscopy &
duodenal biopsy

Usually > 3
mos.

Waking hours
(mornings and
after meals)

Diarrhea

60–70%
worldwide
Lactose
Intolerance

Increases with
age

Genetics:
C/C (-13910) &
T/C (-13910)

Injury or diseases
affecting the small
All ethnicities,
intestine:
but most common
(i.e., bacterial
in Asians,
overgrowth, CD, postAfrican
surgery or
Americans,
chemotherapy etc.)
Indians,
Hispanics

Diarrhea
Nausea
Bloating
Abdominal Cramping
Flatulence
Vomiting

Tests

Process of
elimination.
CBC, CRP, and
(IgA-tTG/
Total IgA)

Rome III Criteria

Post-lactose
ingestion
(usually 1–2 h
after meals)

Lactose
Elimination diet
for 2 wks.
Hydrogen Breath
Test
Lactose
Intolerance Quick
Test
Genetic Testing
C/C (-13910) &
T/C (-13910)

*Systemic Symptoms for CD: Iron-deficiency anemia, lactose intolerance, chronic fatigue, joint pain,
osteoporosis, migraines, depression, irritability, epilepsy, vitamin deficiencies, protein-calorie
malnutrition, short stature, failure to thrive, delayed puberty/early menopause, infertility, dental enamel
defects, recurrent aphthous stomatits, dermatitis herpetiformis, and other autoimmune disorders.
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Figure-1. Systematic Approach for Differentiating CD, LI and IBS

